Novavax Inc. (NVAX)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX
NEW YORK, NY / ACCESSWIRE / October 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Novavax (NVAX) Advances While Market Declines: Some Information for Investors
Novavax (NVAX) closed at $10.35 in the latest trading session, marking a +1.97% move from the prior day.
Novavax Stock Falls After FDA Puts Two Vaccine Programs on Hold
NVAX's COVID-19-flu combination and stand-alone flu vaccines have been placed on hold after a study participant who took the combo shot reported nerve damage.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Novavax, Inc. (NVAX) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESSWIRE / October 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. ("Novavax" or "the Company") (NASDAQ:NVAX). Investors who purchased Novavax securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NVAX.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX
NEW YORK, NY / ACCESSWIRE / October 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Novavax shares tumble after clinical hold on flu combo vaccine
Novavax, Inc. (NASDAQ:NVAX) shares plummeted on Wednesday on news it faced a clinical hold on its CIC flu combination vaccine program after a serious adverse event (SAE) was reported in a Phase 2 trial participant. The SAE, motor neuropathy, surfaced in September 2024, nearly two years after the individual received the vaccine in January 2023.
Novavax Stock Plunges as FDA Puts Hold on Vaccines Because of Safety Concerns
Novavax (NVAX) shares plummeted nearly 20% Wednesday after the Food and Drug Administration (FDA) stopped research on the biotech firm's experimental combination COVID-19 and flu vaccine and standalone flu shot following a report of nerve damage in one patient who took the combination injection.
Novavax, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - NVAX
NEW YORK, NY / ACCESSWIRE / October 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violations of federal securities laws. On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company's combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine.
Novavax says FDA put hold on combination Covid-flu shot and influenza vaccine; shares plunge
Novavax said the Food and Drug Administration has put a hold on its application for a combination shot targeting Covid and influenza and a standalone flu vaccine, sending shares of the company down sharply. The so-called clinical hold is due to a single report of nerve damage in a patient who received the combination shot in a phase two trial that finished in July last year.
Novavax Stock Tumbles 20% as FDA Pauses Clinical Trial on Security Concerns
The regulator placed a clinical hold on its Covid-19-influenza combination vaccine after one person reported nerve damage.
Novavax's stock slides 16% after FDA puts clinical hold on COVID and flu vaccine candidates
Novavax Inc.'s stock tumbled 16% early Wednesday after the company said the FDA has placed a clinical hold on its COVID-19-and-flu combination and stand-alone flu vaccine candidates, following a case of motor neuropathy in a participant in a mid-stage trial.
US FDA places trials of two Novavax vaccines on hold
The U.S. Food and Drug Administration has placed a hold on clinical trials of Novavax's COVID and influenza combination vaccine, as well as standalone flu shot after a serious side-effect was seen in a participant, the company said on Wednesday.
